Potential delays to the Company's project

Current Report No. 19/2022

Date of preparation: 27 May 2022

Subject: Potential delays to the Company's project

Legal basis: Art. 17(1) of MAR – inside information

The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław ("Company") informs that having analysed the information received from external contractors, has identified a potential risk of delays in Project CT-03 (MCL-1) (“Project”) due to limitations in the global availability of key chemical building blocks.

As IND-enabling studies require large amounts of drug substance to be manufactured, there is a risk of a delay of several months in the project, which could mean entering the clinical phase in 2024 (previously Company estimated that the Project will enter first phase of clinical trials by the end of 2023). The Company is continuing to seek alternative solutions to reduce such risk of delay and will keep the market informed of any material developments in accordance with legal requirements.

These potential delays have no impact on the project results to date nor the market potential offered by a first-in-class MCL-1 degrader.